Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Corcept Therapeutics Incorporated/ 144

SEC Filing · 144

Corcept Therapeutics Incorporated

CORTNASDAQEQUITYCurrent

SEC Filing

Filed Aug 26, 2026Accepted Aug 26, 2026, 4:14 PM EDTCIK 1088856Accession 0001950047-26-008710
View company →Permanent SEC source ↗
Share

Company context

For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease.

Current securities

CORTNASDAQ · EQUITY · Current

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 23, 2026
  2. 4 filingSep 16, 2026
  3. 4 filingSep 16, 2026
  4. 144 filingSep 14, 2026
  5. 4 filingAug 28, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗